Guangdong Jiaying Pharmaceutical Co., Ltd

Sümbol: 002198.SZ

SHZ

6.73

CNY

Turuhind täna

121.8232
P/E suhe
10.9641
PEG suhe
3.42B
MRK Cap
0.00%
DIV tootlus

Guangdong Jiaying Pharmaceutical Co., Ltd (002198-SZ) Finantsaruanded

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 307.457 M, mis on 0.183 % gowth. Kogu perioodi keskmine brutokasum on 212.155 M, mis on 0.222 %. Keskmine brutokasumi suhtarv on 0.632 %. Ettevõtte eelmise aasta tulemuse puhaskasv on -0.219 %, mis on võrdne 2.301 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Guangdong Jiaying Pharmaceutical Co., Ltd fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus 0.001. Käibevara valdkonnas on 002198.SZ aruandlusvaluutas 580.174. Märkimisväärne osa neist varadest, täpsemalt 334.037, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust 0.427%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 27.094, kui neid on, aruandlusvaluutas. See näitab erinevust -229.749% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 0 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on -1.000%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 762.985 aruandlusvaluutas. Selle aspekti aastane muutus on 0.047%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 154.048, varude hind on 84.6 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 47.21.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004
balance-sheet.row.cash-and-short-term-investments	1231.73	334	234.1	239.4	142.2	122.3	114.9	82	73.3	46.2	33.3	56.3	21.6	10.5	30.3	32.9	81.9	153.6	37.5	21.5	2.4
balance-sheet.row.short-term-investments	660.9	200.5	50.3	0	0	-51.3	0	-0.3	-4.6	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.net-receivables	657.68	154	240.6	175.7	218.5	202.7	237.9	246.7	250.6	211.2	194.7	159.8	42.8	35.4	34.9	39	70.4	31.8	25.4	11.8	5.2
balance-sheet.row.inventory	347.58	84.6	82.3	73.4	72.8	76.8	71.7	63.3	48.2	47.4	60	55.6	24.4	24.1	16.5	8.4	7.7	8	6.7	7.9	10.6
balance-sheet.row.other-current-assets	5.96	1.1	0.4	1.2	1	7.5	-20.1	-19.8	-21.5	-11	16.1	0.2	-0.6	-1.3	-1	-0.3	-1.5	-3.5	-1.7	-0.9	-0.1
balance-sheet.row.total-current-assets	2267.86	580.2	557.4	489.7	434.5	409.3	404.5	372.3	350.6	293.8	304	271.9	88.2	68.7	80.7	80	158.5	189.8	67.8	40.4	18.1
balance-sheet.row.property-plant-equipment-net	769.11	190.4	203.7	224.2	245.8	255.6	252.2	265	261.3	275.1	245	200.8	146.5	152.4	156	128.2	72.2	50.5	46.4	45.3	47.7
balance-sheet.row.goodwill	0	0	0	0	0	0	120.8	120.8	360.9	360.9	360.9	360.9	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	191.46	47.2	52.4	58.3	64.2	69.5	75.3	81.2	87.1	93	97.4	75.3	3.6	4.2	4.8	5.4	4.4	5.1	5.8	5.5	6.1
balance-sheet.row.goodwill-and-intangible-assets	191.46	47.2	52.4	58.3	64.2	69.5	196.1	202	448	453.9	458.3	436.2	3.6	4.2	4.8	5.4	4.4	5.1	5.8	5.5	6.1
balance-sheet.row.long-term-investments	-134.09	27.1	-20.9	30.6	58.3	113.3	27.6	26.3	25.8	16.5	8.8	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.tax-assets	8.72	2.2	2.2	4.6	5.6	5	8.7	8.7	8.4	6.9	4.6	4.1	1.3	0.5	0.3	0.1	0.2	0.1	0.1	0	0
balance-sheet.row.other-non-current-assets	240.92	0.5	51.8	0	0.1	3.4	0.5	2.3	5.1	1.7	14.6	6	74.7	80.8	59.1	39.6	0	0	0	0	0
balance-sheet.row.total-non-current-assets	1076.11	267.4	289.2	317.7	373.9	446.7	485.1	504.4	748.6	754.2	731.3	647.1	226	237.8	220.1	173.4	76.8	55.6	52.2	50.9	53.8
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	3343.97	847.6	846.7	807.3	808.4	855.9	889.6	876.6	1099.3	1048	1035.3	919	314.2	306.5	300.9	253.3	235.2	245.5	120.1	91.2	71.9
balance-sheet.row.account-payables	42.13	9.2	19	14.1	10.3	15.6	10.2	11.9	11.2	12.3	66.3	17.4	5.7	6.9	6.2	8.4	3.7	4.7	6.3	8.6	13.2
balance-sheet.row.short-term-debt	-2.03	0	5.8	31.1	20.2	96.8	19	40	19.9	30.1	34	15	18.6	22.5	15	0	0	22	22	7.5	0
balance-sheet.row.tax-payables	28.03	7.5	17.2	12	11.2	9.7	17.2	16.9	22.5	20.2	17.4	17.4	0.9	0.5	0.6	0.1	2.7	3.2	4	0.4	0.2
balance-sheet.row.long-term-debt-total	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7.5	0	0	0	0	0	0
Deferred Revenue Non Current	1.72	0.4	0.5	0.2	0.2	0.3	0.3	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	139.12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	118.62	40.2	47.1	5.7	3.1	7.4	22.7	5.8	5.9	3.6	6.1	7.6	4.3	4	5	3.5	5.2	0.2	0.1	0.1	9.8
balance-sheet.row.total-non-current-liabilities	140.84	35.2	35.3	34.9	35	35	35	35.2	34.7	34.7	34.7	34.7	0	0	7.5	0	0	0	0	0	0
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	315.92	84.6	118.2	122.9	125.4	192.8	104.2	126.8	114.4	118.3	171.9	109.3	36.2	36	42.4	11.9	8.9	32.9	37.4	26.8	22.9
balance-sheet.row.preferred-stock	54.45	27.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	2030.04	507.5	507.5	507.5	507.5	507.5	507.5	507.5	507.5	507.5	507.5	253.8	205	205	164	82	82	82	61.5	49.2	45.3
balance-sheet.row.retained-earnings	398.09	104.6	70.3	26.3	24.9	5	127.2	91.7	326.7	276.6	211.6	158.9	30.1	23.7	55.2	65.3	51.7	39.4	17.4	12.9	3
balance-sheet.row.accumulated-other-comprehensive-income-loss	174.76	0	27.2	27.2	27.2	27.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	370.71	123.7	123.4	123.4	123.4	123.4	150.6	150.6	150.6	145.6	144.2	397	43	41.8	39.3	94.1	92.6	91.3	3.7	2.3	0.7
balance-sheet.row.total-stockholders-equity	3028.05	763	728.4	684.5	683	663.2	785.4	749.8	984.9	929.7	863.3	809.7	278.1	270.5	258.5	241.4	226.3	212.6	82.6	64.4	49
balance-sheet.row.total-liabilities-and-stockholders-equity	3343.97	847.6	846.7	807.3	808.4	855.9	889.6	876.6	1099.3	1048	1035.3	919	314.2	306.5	300.9	253.3	235.2	245.5	120.1	91.2	71.9
balance-sheet.row.minority-interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	3028.05	763	728.4	684.5	683	663.2	785.4	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	3343.97	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	105.91	27.1	29.4	30.6	58.3	61.9	27.5	26	21.2	16.5	8.8	0	70.4	76.2	54.2	34.5	0	0	0	0	0
balance-sheet.row.total-debt	5.87	0	5.8	31.1	20.2	96.8	19	40	19.9	30.1	34	15	18.6	22.5	22.5	0	0	22	22	7.5	0
balance-sheet.row.net-debt	-564.95	-133.5	-178.1	-208.3	-122.1	-25.5	-95.9	-42	-53.4	-16.1	0.7	-41.3	-3	12	-7.8	-32.9	-81.9	-131.6	-15.5	-14	-2.4

Rahavoogude aruanne

Guangdong Jiaying Pharmaceutical Co., Ltd finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab 2.825 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 0, mis tähistab 0.000 erinevust võrreldes eelmise aastaga. Huvitav on see, et osa ettevõtte aktsiatest, täpsemalt 0, ostis ettevõte ise tagasi. Selle tegevuse tulemusena muutus 0.000 võrreldes eelmise aastaga. Vahepeal on ettevõtte võlgnevused praegu 44.11 aruandlusvaluutas. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli -51031607.190. See on -1.924 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 25.89, -49.91, -31.11, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte -0.45 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui 0, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	TTM	2021	2019	2017	2015	2013	2011	2009	2007	2005
cash-flows.row.net-income	27.32	43.9	1.5	19.8	-122.2	35.9	-214.8	55.2	66.4	73.7	139.5	7	20.2	25.2	15.1	13.7	24.4	22.1	15.4	2.8
cash-flows.row.depreciation-and-amortization	18.01	25.9	28.4	28.2	27.2	27.1	26.7	25.7	21.4	23.5	14.9	14.8	14.5	11.9	7.5	6.3	5.4	4.3	4.1	2
cash-flows.row.deferred-income-tax	0	2.4	1	-0.6	3.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	0	-2.4	-1	0.6	-3.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	116.01	-48.4	-4.8	38.8	-16.1	-6.1	-27.5	-32.1	-46.1	0.7	11.6	-1.4	-14.4	1.1	11.4	-10	-13.3	-0.8	-2.7	3.6
cash-flows.row.account-receivables	118.37	-86.5	9.6	9	-8.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	-2.36	-8.4	-0.8	2.5	-4.9	-8.9	-14.5	-2.1	12.6	-4.4	-8.5	-0.3	-7.6	-8.2	-0.7	0.3	-1.4	1.3	2.7	-3.5
cash-flows.row.account-payables	0	44.1	-14.7	27.9	-6.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	0	2.4	1	-0.6	3.8	2.8	-13	-30	-58.6	5.1	20.1	-1.1	-6.8	9.3	12.1	-10.3	-11.9	-2.1	-5.3	7.2
cash-flows.row.other-non-cash-items	-48.06	5.7	26.7	10	124.1	5.2	246.1	4.3	0.7	5.5	-146.5	-15.2	-19.5	-18.6	-6	0.6	1.8	0.8	0.8	0.4
cash-flows.row.net-cash-provided-by-operating-activities	113.28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-12.26	-2.7	-2.3	-11.7	-18.8	-8.9	-18.4	-12	-33.4	-98.7	-8.7	-6.6	-10.8	-35.6	-76.9	-29.1	-8.7	-12.9	-6.1	-18
cash-flows.row.acquisitions-net	141.97	0.1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.purchases-of-investments	0	-0.1	0	0	-86.3	0	-4.3	-2.5	-7	-8.8	0	0	0	0	0	-28.9	0	0	0	0
cash-flows.row.sales-maturities-of-investments	-126.83	1.6	32.5	18.5	0	0	0	0	0	0	5.3	17.8	0	0	0	0	0	0	0	0
cash-flows.row.other-investing-activites	-180	-49.9	25.1	-25	0	2.2	2.5	0.1	16.3	-15.8	37.1	0	0	0	0	0	0	0	0.1	0
cash-flows.row.net-cash-used-for-investing-activites	-176.93	-51	55.2	-18.2	-105.1	-6.8	-20.2	-14.4	-23.1	-123.2	33.7	11.2	-10.8	-35.6	-76.9	-57.9	-8.7	-12.9	-6	-18
cash-flows.row.debt-repayment	0	-31.1	-15	-135	-19	-58	-19.9	-30.1	-41	-15	-18.6	-22.5	-15	-7.5	0	-22	-22	-15	0	0
cash-flows.row.common-stock-issued	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	0	-0.5	-1	-3.8	-3.5	-1.3	-21.9	-1.4	-2.4	-22.2	-7.6	-1.4	-9.8	-9.1	0	-0.5	-1.4	-5.1	0	0
cash-flows.row.other-financing-activites	0	0	31.1	55	122	37	40	19.9	45.6	26.7	6.6	18.6	15	30	0	-2	129.8	22.6	7.5	6.9
cash-flows.row.net-cash-used-provided-by-financing-activities	0	-31.6	15.1	-83.8	99.5	-22.3	-1.8	-11.6	2.2	-10.5	-19.6	-5.4	-9.8	13.4	0	-24.5	106.4	2.6	7.5	6.9
cash-flows.row.effect-of-forex-changes-on-cash	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	-64.89	-55.4	122.1	-5.1	7.4	33	8.6	27.1	21.4	-30.4	33.6	11.1	-19.8	-2.6	-49	-71.7	116	16	19.1	-2.4
cash-flows.row.cash-at-end-of-period	567.95	183.9	239.3	117.2	122.3	114.9	82	73.3	46.2	24.8	55.2	21.6	10.5	30.3	32.9	81.9	153.6	37.5	21.5	2.4
cash-flows.row.cash-at-beginning-of-period	632.85	239.3	117.2	122.3	114.9	82	73.3	46.2	24.8	55.2	21.6	10.5	30.3	32.9	81.9	153.6	37.5	21.5	2.4	4.8
cash-flows.row.operating-cash-flow	113.28	27.2	51.8	96.9	13	62.1	30.6	53.1	42.3	103.4	19.5	5.3	0.8	19.7	28	10.7	18.3	26.4	17.6	8.8
cash-flows.row.capital-expenditure	-12.26	-2.7	-2.3	-11.7	-18.8	-8.9	-18.4	-12	-33.4	-98.7	-8.7	-6.6	-10.8	-35.6	-76.9	-29.1	-8.7	-12.9	-6.1	-18
cash-flows.row.free-cash-flow	101.02	24.4	49.5	85.2	-5.9	53.2	12.2	41.1	8.9	4.6	10.7	-1.3	-10	-15.9	-49	-18.3	9.7	13.4	11.5	-9.3

Kasumiaruande rida

Guangdong Jiaying Pharmaceutical Co., Ltd tulud muutusid võrreldes eelmise perioodiga -0.191%. 002198.SZ brutokasum on teatatud 347.72. Ettevõtte tegevuskulud on 310.41, mille muutus võrreldes eelmise aastaga on -17.437%. Kulud amortisatsioonikulud on 25.89, mis on -0.091% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 310.41, mis näitab -17.437% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -0.248% kasvu võrreldes eelmise aastaga. Tegevustulu on 40.52, mis näitab -0.248% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on -0.219%. Eelmise aasta puhaskasum oli 34.32.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004
income-statement-row.row.total-revenue	499.15	533.2	659.2	574.7	544.7	500.5	537	468.1	450	475.8	565.8	226.7	104.5	85.9	75.2	62.3	66.3	64.6	62.7	54.3	37.5
income-statement-row.row.cost-of-revenue	184.54	185.5	228.5	141.9	146.5	106.4	144	125	104.7	126.7	221.3	96.8	52.1	45.1	34.2	25.8	26.9	23.9	24.1	24.6	22
income-statement-row.row.gross-profit	314.61	347.7	430.7	432.8	398.2	394.1	393	343	345.2	349.1	344.6	130	52.4	40.8	41	36.5	39.5	40.7	38.6	29.7	15.5
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	10.47	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	13.37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	219.49	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	-1.19	-1.1	40.7	46.3	42.9	47.1	0.5	1.1	0	3.9	11.4	4	2	1.2	3.5	2.7	2.6	6.4	1.6	0.5	0.5
income-statement-row.row.operating-expenses	285.61	310.4	376	403.2	365.2	384.6	346.1	304.6	274.5	274.2	263.1	101.2	62	40.7	36.8	28.6	27.4	15.3	14.9	13.5	12.3
income-statement-row.row.cost-and-expenses	470.15	495.9	604.5	545.1	511.7	491	490.1	429.6	379.2	400.9	484.3	198	114.1	85.8	71	54.4	54.2	39.1	39	38.1	34.2
income-statement-row.row.interest-income	2.17	2.1	2.3	2.6	1.1	0.5	0.4	0.3	0.1	0.2	0.3	0.1	0	0.2	0.2	0.3	1.3	0.2	0.2	0	0
income-statement-row.row.interest-expense	0	0	0.5	1	3.7	3.5	1.8	1.8	1.5	2.4	2.2	1.5	1.4	1.6	0.9	0	0.5	1.5	0.3	0.5	0.5
income-statement-row.row.selling-and-marketing-expenses	219.49	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	0.14	2.1	-2.8	-27.8	-1	-123.1	-4.6	-244.3	-4.1	3.4	5.8	150.5	16.7	20.7	21.9	8.9	3.9	3.3	0.9	-0.8	-0.4
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	-1.19	-1.1	40.7	46.3	42.9	47.1	0.5	1.1	0	3.9	11.4	4	2	1.2	3.5	2.7	2.6	6.4	1.6	0.5	0.5
income-statement-row.row.total-operating-expenses	0.14	2.1	-2.8	-27.8	-1	-123.1	-4.6	-244.3	-4.1	3.4	5.8	150.5	16.7	20.7	21.9	8.9	3.9	3.3	0.9	-0.8	-0.4
income-statement-row.row.interest-expense	0	0	0.5	1	3.7	3.5	1.8	1.8	1.5	2.4	2.2	1.5	1.4	1.6	0.9	0	0.5	1.5	0.3	0.5	0.5
income-statement-row.row.depreciation-and-amortization	8.91	24.2	26.6	28.4	33.5	27.2	27.1	26.7	25.7	21.4	23.5	14.9	14.8	14.5	11.9	7.5	6.3	5.4	4.3	4.1	2
income-statement-row.row.ebitda-caps	30.17	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	33.65	40.5	53.9	33.6	24.1	8.9	41.8	-206.9	66.7	74.4	76.2	176.3	5	19.6	22.7	14	12.7	23.7	23.1	15.5	2.8
income-statement-row.row.income-before-tax	32.46	39.4	51.1	5.8	23	-114.2	42.3	-205.8	66.6	78.2	87.3	179.3	7	20.8	26.2	16.8	16.1	28.8	24.6	15.4	2.8
income-statement-row.row.income-tax-expense	5.15	5.1	7.2	4.3	3.2	8	6.5	8.9	11.5	11.9	13.7	39.8	-0.5	0.6	0.9	1.7	2.3	4.4	2.5	0	0.1
income-statement-row.row.net-income	27.32	34.3	43.9	1.5	19.8	-122.2	35.9	-214.8	55.2	66.4	73.7	139.5	7.6	20.2	25.2	15.1	13.7	24.4	22.1	15.4	2.8